These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26331432)

  • 1. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
    Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
    Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
    Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
    Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
    Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
    Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
    Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
    Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
    Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
    Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
    Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
    Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
    Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
    Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
    Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
    [No Abstract]   [Full Text] [Related]  

  • 13. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
    Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
    Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
    Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
    Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.